Clinical Trials Logo

Fibromyalgia clinical trials

View clinical trials related to Fibromyalgia.

Filter by:

NCT ID: NCT01619566 Withdrawn - Fibromyalgia Clinical Trials

Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed

Start date: June 2012
Phase: Phase 4
Study type: Interventional

Subjects with Fibromyalgia who respond to Duloxetine have specific nerve fiber characteristics. This can be used to predict which future patients will respond to Duloxetine.

NCT ID: NCT01397006 Withdrawn - Fibromyalgia Clinical Trials

Fibromyalgia of Less Than One Year Duration. Study of Pregabalin

Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate whether pregabalin is effective in treating subjects who have had fibromyalgia for less than one year. Pregabalin has been approved by the FDA for treatment of fibromyalgia. the purpose of the study is to see if subjects identified through their primary care physicians who have fibromyalgia and have had symptoms for less than one year respond to pregabalin and to identify characteristics of that response.

NCT ID: NCT01359826 Withdrawn - Fibromyalgia Clinical Trials

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

Start date: October 2011
Phase: Phase 4
Study type: Interventional

Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease impacting the physical, social, psychological health and quality of life of patients. Fatigue and pain are aspects of SLE patients which affect their health related quality of life (HRQOL). The purpose of this study is to determine the effect of milnacipran on fatigue in SLE patients with widespread pain (WSP) or fibromyalgia syndrome (FMS). A secondary objective will be to determine the effect of milnacipran on pain and quality of life measurements. Fifty SLE male and female patients, 18 years and older, will be recruited for a 15-week study, in which patients will be receive 14 weeks of milnacipran 50-100 mg twice a day or placebo. Measurements of fatigue, pain, and HRQOL will be compared between the milnacipran and placebo groups at the screening visit, baseline visit, week number 6, and week number 14. Milnacipran has been shown to be an effective treatment for pain, fatigue and physical function in FMS patients. To date, no clinical trials have demonstrated efficacy for the treatment of fatigue in SLE patients with concomitant WSP or FMS. The investigators hypothesize, based on FMS studies, that the milnacipran treated patients will have less fatigue than those in the placebo group. In addition, compared to control arm, those treated with the study drug will have less pain and improved quality of life.

NCT ID: NCT01089621 Withdrawn - Fibromyalgia Clinical Trials

A Study for Adolescents With Fibromyalgia Syndrome

Start date: March 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the possibility of conducting a larger study in adolescents with fibromyalgia syndrome.

NCT ID: NCT00855972 Withdrawn - Fibromyalgia Clinical Trials

Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome

Start date: August 2010
Phase: N/A
Study type: Interventional

The purpose of this research is to obtain data or information on the safety and effectiveness of low dose naltrexone (LDN) for treating the symptoms of juvenile primary fibromyalgia syndrome. This is a dose finding study to find whether LDN helps the symptoms of juvenile fibromyalgia, and at what dose it does so.

NCT ID: NCT00796601 Withdrawn - Fibromyalgia Clinical Trials

Maintenance of Efficacy.

Start date: May 1, 2009
Phase: Phase 3
Study type: Interventional

The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.

NCT ID: NCT00795106 Withdrawn - Clinical trials for Myofascial Pain Syndrome

Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain

Start date: November 2009
Phase: Phase 2
Study type: Interventional

Chronic neck pain is a common condition that can negatively impact quality of life. Substance P is one of the chemicals in the body that can transmit pain signals from overloaded neck muscles to the brain. Topical capsaicin blocks the action of Substance P by releasing, and subsequently depleting the body's store of Substance P in the nerves. Topical capsaicin has been reported to be an effective therapy for a number of persistent pain conditions including diabetic neuropathy, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, and post-mastectomy pain. This study will evaluate the efficacy of topical capsaicin to reduce pain and improve health-related quality of life in adults with chronic muscular neck pain.

NCT ID: NCT00754884 Withdrawn - Fibromyalgia Clinical Trials

Calcitonin in the Treatment of Fibromyalgia

CALFI
Start date: October 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether nasal administration of salmon calcitonin is effective and safe in the treatment of symptoms and signs of primary fibromyalgia.

NCT ID: NCT00259636 Withdrawn - Fibromyalgia Clinical Trials

Zonisamide for Fibromyalgia & Migraine

Start date: August 2004
Phase: Phase 4
Study type: Interventional

Patients with fibromyalgia & migraine are randomized to receive zonisamide or placebo.